IAP
NVO

Indie Asset Partners’s Novo Nordisk NVO Stock Holding History

Indie Asset Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,032
Closed -$211K – 96
2025
Q1 		$211K Sell
3,032
-96
-3% -$7.93K 0.18% 90
2024
Q4 		$269K Buy
3,128
+126
+4% +$13.6K 0.21% 83
2024
Q3 		$357K Hold
3,002
– – 0.27% 63
2024
Q2 		$429K Buy
3,002
+700
+30% +$92.8K 0.34% 46
2024
Q1 		$296K Hold
2,302
– – 0.26% 61
2023
Q4 		$238K Sell
2,302
-320
-12% -$31.6K 0.21% 67
2023
Q3 		$238K Hold
2,622
– – 0.24% 60
2023
Q2 		$212K Hold
2,622
– – 0.23% 72
2023
Q1 		$209K Buy
+2,622
New +$186K 0.24% 75
2022
Q3 		– Sell
-5,072
Closed -$283K – 101
2022
Q2 		$283K Sell
5,072
-200
-4% -$11.1K 0.25% 70
2022
Q1 		$293K Sell
5,272
-186
-3% -$9.55K 0.22% 88
2021
Q4 		$306K Buy
+5,458
New +$296K 0.22% 92

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Indie Asset Partners's NVO Position: Q2 2025 in Review

Indie Asset Partners sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 3,032 shares — an estimated $211K sold.

Indie Asset Partners first reported a position in NVO in Q4 2021 and held it in 12 quarters. The position peaked at $429K in Q2 2024. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • Indie Asset Partners reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • Indie Asset Partners sold 3,032 Novo Nordisk shares in Q2 2025, an estimated $211K.
  • Indie Asset Partners first reported a position in Novo Nordisk in Q4 2021 and held it in 12 quarters.
  • Indie Asset Partners's Novo Nordisk position peaked at $429K in Q2 2024.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Indie Asset Partners's 13F filing for Q2 2025, filed 12 Aug 2025.